Scientific Presentations for Products in Development

Clovis Oncology presents data on its products in development at a variety of medical conferences. Our current and historic presentations are provided in the following links.

Evaluation of Brain Pharmacokinetics (PK) and Tumor Growth Inhibition of PARP Inhibitors in Mouse Xenograft Models Using Semi-Mechanistic PK/Pharmacodynamic (PD) Modeling

Poster Presentation 2020 AACR Virtual Meeting II

documentImage.GetPropertyValue(

Application of Machine Learning and Grid Search Approaches to Minimize Lucitanib Pharmacokinetic Variability Following Different Dosing Regimens

Poster Presentation 2020 AACR Virtual Meeting II

documentImage.GetPropertyValue(

The Combination of a Mouse Ortholog of ALKS 4230, a Selective Agonist of the Intermediate-Affinity IL-2 Receptor, and the Angiogenesis Inhibitor Lucitanib Enhances Antitumor Activity

Poster Presentation 2020 AACR Virtual Meeting II

documentImage.GetPropertyValue(

Characterization of Patients With Long-term Responses to Rucaparib in Recurrent Ovarian Cancer

Virtual Presentation 2020 ASCO

documentImage.GetPropertyValue(

Postprogression Outcomes in Patients With Ovarian Carcinoma Associated With a Mutation in a Non-<i>BRCA</i>Homologous Recombination Repair Gene Receiving Rucaparib Maintenance Treatment: Results From the Phase 3 Study ARIEL3

Webinar Presentation 2020 SGO

documentImage.GetPropertyValue(

Population Exposure-Safety and Exposure-Efficacy Analyses for Rucaparib in Patients With Recurrent Ovarian Carcinoma From Study 10 and ARIEL2

Poster Presentation 2020 SGO

documentImage.GetPropertyValue(

Rucaparib for recurrent, locally advanced or metastatic urothelial carcinoma: results from ATLAS, a phase 2, open-label trial

Presented at 2020 ASCO GU

documentImage.GetPropertyValue(

Genomic characteristics associated with clinical activity of rucaparib in patients (pts) with <i>BRCA1</i> or <i>BRCA2</i> (<i>BRCA</i>)-mutated metastatic castration-resistant prostate cancer (mCRPC)

Presented at 2020 ASCO GU

documentImage.GetPropertyValue(

Combination of the Angiogenesis Inhibitor Lucitanib with Immune Checkpoint Blockade Augments Anti-tumor Activity in Syngeneic Models

Presented at 2019 SITC

documentImage.GetPropertyValue(

ATHENA (GOG-3020/ENGOT-ov45): A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Poly(ADP-Ribose) Polymerase (PARP) Inhibitor Rucaparib + the PD-1 Inhibitor Nivolumab Following Frontline Platinum-Based Chemotherapy in Ovarian Cancer

Presented at 2019 ASGO

documentImage.GetPropertyValue(

Integrated safety analysis of the poly(ADP-ribose) polymerase inhibitor rucaparib in patients with ovarian cancer in the treatment and maintenance settings

Presented at 2019 ESMO

documentImage.GetPropertyValue(

Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment

Presented at 2019 ESMO

documentImage.GetPropertyValue(

Preliminary results from the TRITON2 study of rucaparib in patients (pts) with DNA damage repair (DDR)-deficient metastatic castration-resistant prostate cancer (mCRPC): updated analyses

Presented at 2019 ESMO

documentImage.GetPropertyValue(

ARIES: A Phase 2, Open-Label Study to Evaluate Rucaparib (PARP Inhibitor) in Combination with Nivolumab (Anti-PD-1 Antibody) in Patients with Ovarian Cancer

Presented at 2019 IGCS

documentImage.GetPropertyValue(